Cargando…
Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
BACKGROUND: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714102/ https://www.ncbi.nlm.nih.gov/pubmed/31462302 http://dx.doi.org/10.1186/s40425-019-0709-7 |
_version_ | 1783446989623525376 |
---|---|
author | Tan, Qin Zhang, Chaoting Yang, Wenjun Liu, Ying Heyilimu, Palashati Feng, Dongdong Xing, Liying Ke, Yang Lu, Zheming |
author_facet | Tan, Qin Zhang, Chaoting Yang, Wenjun Liu, Ying Heyilimu, Palashati Feng, Dongdong Xing, Liying Ke, Yang Lu, Zheming |
author_sort | Tan, Qin |
collection | PubMed |
description | BACKGROUND: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could induce immune response in epithelial cancer and additionally many tumor-specific antigens could be derived from noncoding region. Autologous tumor cells (ATCs) could be unbiased stimulators in activating and enriching tumor-reactive T cells. However, it’s unknown if T cells engineered to express TCRs isolated from tumor-reactive T cells enriched by ATCs have strong antitumor response. METHODS: In this study, multiple TIL fragments obtained from a patient with esophageal squamous cell carcinoma (ESCC) were screened for specific recognition of ATCs. Tumor-reactive TILs were enriched by in vitro repeated stimulation of ATCs and isolated based on CD137 upregulation. Subsequently, tumor-reactive TCR was obtained by single-cell RT-PCR analysis and was introduced into peripheral blood lymphocytes to generate TCR-Ts. RESULTS: We found that phenotype and effect function of TIL fragments derived from different tumor sites were spatially heterogeneous. Of four TIL fragments, only TIL-F1 could specifically identify ATCs. Subsequently, we isolated CD8(+) CD137(+) T cells from pre- and post-stimulated TIL-F1 co-cultured with ATCs, and identified their most dominant TCR. This TCR was introduced into PBLs to generate TCR-Ts, which specifically identified and killed ATCs in vivo and in vitro. CONCLUSION: This strategy provides the means to generate tumor-reactive TCR-Ts for ESCC, which is especially important for patients without prior knowledge of specific epitopes and might be applied for other cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0709-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6714102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67141022019-09-04 Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma Tan, Qin Zhang, Chaoting Yang, Wenjun Liu, Ying Heyilimu, Palashati Feng, Dongdong Xing, Liying Ke, Yang Lu, Zheming J Immunother Cancer Research Article BACKGROUND: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could induce immune response in epithelial cancer and additionally many tumor-specific antigens could be derived from noncoding region. Autologous tumor cells (ATCs) could be unbiased stimulators in activating and enriching tumor-reactive T cells. However, it’s unknown if T cells engineered to express TCRs isolated from tumor-reactive T cells enriched by ATCs have strong antitumor response. METHODS: In this study, multiple TIL fragments obtained from a patient with esophageal squamous cell carcinoma (ESCC) were screened for specific recognition of ATCs. Tumor-reactive TILs were enriched by in vitro repeated stimulation of ATCs and isolated based on CD137 upregulation. Subsequently, tumor-reactive TCR was obtained by single-cell RT-PCR analysis and was introduced into peripheral blood lymphocytes to generate TCR-Ts. RESULTS: We found that phenotype and effect function of TIL fragments derived from different tumor sites were spatially heterogeneous. Of four TIL fragments, only TIL-F1 could specifically identify ATCs. Subsequently, we isolated CD8(+) CD137(+) T cells from pre- and post-stimulated TIL-F1 co-cultured with ATCs, and identified their most dominant TCR. This TCR was introduced into PBLs to generate TCR-Ts, which specifically identified and killed ATCs in vivo and in vitro. CONCLUSION: This strategy provides the means to generate tumor-reactive TCR-Ts for ESCC, which is especially important for patients without prior knowledge of specific epitopes and might be applied for other cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0709-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-28 /pmc/articles/PMC6714102/ /pubmed/31462302 http://dx.doi.org/10.1186/s40425-019-0709-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tan, Qin Zhang, Chaoting Yang, Wenjun Liu, Ying Heyilimu, Palashati Feng, Dongdong Xing, Liying Ke, Yang Lu, Zheming Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma |
title | Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma |
title_full | Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma |
title_fullStr | Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma |
title_full_unstemmed | Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma |
title_short | Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma |
title_sort | isolation of t cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of t cell receptor engineered t cells for esophageal squamous cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714102/ https://www.ncbi.nlm.nih.gov/pubmed/31462302 http://dx.doi.org/10.1186/s40425-019-0709-7 |
work_keys_str_mv | AT tanqin isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT zhangchaoting isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT yangwenjun isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT liuying isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT heyilimupalashati isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT fengdongdong isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT xingliying isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT keyang isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma AT luzheming isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma |